Barnett J C, Touchon R C
West Virginia University Health Sciences Center, Huntington.
Chest. 1990 May;97(5):1106-9. doi: 10.1378/chest.97.5.1106.
Nineteen consecutive patients with atrial fibrillation/flutter or other types of supraventricular tachycardia were given intravenous (IV) calcium salts (1 g) followed by verapamil infusion at a rate of 1 mg/min. Successful treatment was defined as control of ventricular response to less than or equal to 100 beats per minute (bpm) or conversion to sinus mechanism in patients with atrial arrhythmias: 11 patients had atrial fibrillation; three had atrial flutter; four had reentrant supraventricular tachycardias (SVT); and one had paroxysmal SVT. Therapy was successful in all patients. The mean dose of verapamil required to achieve desired outcome was 20 mg. Heart rate showed no significant change as a result of calcium pretreatment (160 bpm v 151 bpm). However, heart rate was significantly decreased, to 95 bpm, after treatment with verapamil. Blood pressure showed no change from baseline with either calcium or verapamil therapy. Verapamil infusion following IV calcium successfully treats atrial fibrillation/flutter or SVTs without depressing systemic blood pressure.
对19例连续性心房颤动/扑动或其他类型室上性心动过速患者静脉注射(IV)钙剂(1 g),随后以1 mg/min的速率输注维拉帕米。成功治疗定义为将心室反应控制在每分钟100次或以下(bpm),或使房性心律失常患者转为窦性心律机制:11例为心房颤动;3例为心房扑动;4例为折返性室上性心动过速(SVT);1例为阵发性SVT。所有患者治疗均成功。达到预期结果所需的维拉帕米平均剂量为20 mg。钙剂预处理后心率无显著变化(160 bpm对151 bpm)。然而,维拉帕米治疗后心率显著降低至95 bpm。钙剂或维拉帕米治疗后血压与基线相比均无变化。静脉注射钙剂后输注维拉帕米可成功治疗心房颤动/扑动或SVT,且不降低全身血压。